Close Menu

NEW YORK – Lucira Health, a startup formerly known as Diassess, announced today it has closed a $15 million Series B equity financing round.

The Emeryville, California-based developer of instrument-free, molecular diagnostics for infectious disease testing intends to use the funds to finance regulatory clearances and early commercialization.

The funding was led by Seraph Group with participation from Eclipse Ventures, DCVC (Data Collective), Y Combinator, Sunstone Management, and ShangBay Capital, the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.